Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
May 24, 2021
Hackensack Meridian Health, New Jersey's largest, most comprehensive and integrated health network, and Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., have entered into a...
-
Apr 19, 2021Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Michel Vounatsos, "Biogen") today announced...
-
Apr 16, 2021Twenty-one presentations featuring data and information on investigational lecanemab in early Alzheimer's disease, DAYVIGO® (lemborexant) CIV in insomnia, FYCOMPA® (perampanel) CIII in epilepsy and investigational lorcaserin in Dravet Syndrome
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today that data from the company's deep neurology pipeline and portfolio, including Alzheimer's disease, insomnia and...
-
Mar 16, 2021
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that anti-microtubule binding region (MTBR) tau antibody E2814, which was created from collaboration research...
-
Mar 5, 2021- Oral presentations and posters highlighting Eisai's investigational novel therapies and immunoassay system being studied for Alzheimer's disease and its clinical symptoms
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., announced today the presentation of data and information from the company's robust Alzheimer's disease (AD) pipeline, including...